In prostate cancer, approximately ten JNK-activating natural compounds (e.g. jungermannenone B62, capilliposide C63, guttiferone F64 and others51) have been identified to date and were reported to induce cell cycle arrest and apoptosis in vitro. Here, MAPK8 is linked to prostate carcinoma.